http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2017132742-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_19d47a9a7350624411cfa37a23b9bba1 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 |
| filingDate | 2016-01-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0fd00e63d743098466df9b954cef216d |
| publicationDate | 2017-08-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2017132742-A |
| titleOfInvention | Novel pharmacological use of Aβ oligomer specific antibody |
| abstract | The present invention targets a preventive preemptive medicine for Alzheimer type dementia (AD), which cannot be realized by the prior invention, and has a complementarity determining region having an effect of preventing the onset of cognitive dysfunction equivalent to the antibody of the prior invention. The object is to provide (CDR) peptides. According to the present invention, there is provided a pharmaceutical composition comprising a specific CDR functional peptide having a novel pharmacological use for an antibody that specifically binds to a neurotoxic Aβ oligomer. [Selection figure] None |
| priorityDate | 2016-01-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 68.